Navigation Links
Rigel Announces First Quarter Financial Results

SOUTH SAN FRANCISCO, Calif., May 3, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2011.

For the first quarter of 2011, Rigel reported a net loss of $20.8 million, or $0.40 per share, compared to a net loss of $22.3 million, or $0.43 per share, in the first quarter of 2010. Weighted average shares outstanding for the first quarter of 2011 and 2010 were 52.3 million and 52.0 million, respectively.

There was no contract revenue reported in the first quarter of 2011. Contract revenue in the first quarter of 2010 was $3.3 million from the initial amortization of the $100.0 million upfront payment in connection with the exclusive worldwide license agreement with AstraZeneca AB (AZ) for fostamatinib.

Rigel reported total operating expenses of $20.9 million in the first quarter of 2011, compared to $25.6 million in the first quarter of 2010. The decrease in operating expenses was primarily due to a decrease in clinical development expenses, certain one-time investment banking fees associated with the closing of our transaction with AZ in 2010, and a decrease in stock-based compensation expense. The decrease in clinical development expenses was primarily due to the completion of the transfer of the fostamatinib open label extension study to AZ in September 2010. Stock-based compensation expense decreased from approximately $5.2 million in the first quarter of 2010 to approximately $3.8 million in the first quarter of 2011.

As of March 31, 2011, Rigel had cash, cash equivalents and available for sale securities of $155.5 million, compared to $177.3 million as of December 31, 2010.  Rigel expects to end 2011 with over $105.0 million in cash, cash equivalents and available for sale securities, which is expected to be sufficient to fund operations into 2013.

"We are delighted by the progress AstraZeneca has made with the fostamatinib phase 3 program," said James M. Gower, chairman and chief executive officer of Rigel. "We currently expect to begin two phase 1 clinical trials with our internal JAK3 programs by the end of 2011. The first is a novel oral JAK3 inhibitor intended for the treatment of transplant rejection and the second is a different JAK3 inhibitor in a topical formulation intended for the treatment of discoid lupus," he added.

About Rigel (

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral syk inhibitor that has started its phase 3 clinical trial program for rheumatoid arthritis, and R343, an inhaled syk inhibitor that has completed Phase 1 clinical trials for asthma.

This press release contains "forward-looking" statements, including, without limitation, statements related to Rigel's expectations as to its year-end cash position and the sufficiency of its cash, cash equivalents and available for sale securities; and identification of a novel programs for clinical development, the potential indications for treatment, and the timing of clinical trials with respect thereto.  Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as " "intend," "expect," and similar expressions are intended to identify these forward-looking statements. These forward-looking statements are based upon Rigel's current expectations and involve risks and uncertainties. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including, without limitation, risks associated with Rigel's need for additional capital, the timing and success of preclinical studies and clinical trials and the potential problems that may arise in the research and development and approval process, as well as other risks detailed from time to time in Rigel's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2010. Rigel does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

Contact: Ryan D. Maynard
Phone: 650.624.1284

Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.
Phone: 650.430.3777
Email: susan@alchemyemail.comSTATEMENTS OF OPERATIONS(in thousands, except per share amounts)Three Months Ended March 31,20112010(unaudited)Revenues:Contract revenues


3,261Operating expenses:Research and development (see Note A)


17,425General and administrative (see Note A)


8,186Total operating expenses


25,611Loss from operations


(22,350)Interest income, net


17Net loss


(22,333)Net loss per share, basic and diluted


(0.43)Weighted-average shares used in computing net loss per share, basic and diluted


51,964Note AStock-based compensation expense included in:Research and development


3,083General and administrative



5,167SUMMARY BALANCE SHEET DATA(in thousands)March 31,December 31,20112010 (1) (unaudited) Cash, cash equivalents and availablefor sale securities


77,295Total assets


186,695Stockholders' equity


166,131(1)  Derived from audited financial statements

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Rigel Announces Fourth Quarter and Year End 2010 Financial Results
2. Rigel to Present at Three Upcoming Investor Conferences
3. Rigel Announces Participation at Two Investor Conferences
4. Rigel to Present at JP Morgan Healthcare Conference
5. Rigel Announces Third Quarter 2009 Financial Results
6. Rigel Announces Presentations at Two Investor Conferences
7. Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
8. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
9. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
10. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
11. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
Post Your Comments:
(Date:11/25/2015)... 2015  Linden Care, LLC, a retail specialty pharmacy ... patients suffering from chronic pain, said today that it ... Order (TRO) enjoining Express Scripts from unilaterally terminating the ... --> --> The company said ... options. --> --> ...
(Date:11/25/2015)... 25, 2015  ARKRAY USA , ... provide evidence demonstrating the accuracy of its blood glucose ... Insulin Resistance, Diabetes and Cardiovascular Disease in ... Company,s GLUCOCARD ® 01 meter and the Assure ... The ability to accurately measure glucose levels in blood ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan plc (NYSE: ... with the New York State Attorney ... the Sherman Act, and other statutes with the Attorney General ... 2014, to cease marketing and selling the now generic version ... Allergan admits no liability, has released its counterclaims against ...
Breaking Medicine Technology:
(Date:11/25/2015)... Cleveland, OH (PRWEB) , ... November 25, 2015 , ... ... dental implants in Cleveland, OH , are invited to attend Dr. Mark Iacobelli’s Advanced ... 5th this year in Cleveland, OH. , As the co-founders of Advanced Implant ...
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law ... successful appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys ... Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, Adcock ...
(Date:11/25/2015)... ... ... SCOTTSDALE, AZ) - Today, Dr. Todd C. Hobgood ... non-surgical treatments, announced the expansion of his private practice capabilities with the grand ... trained and nationally recognized for his natural approach, Dr. Todd Hobgood serves the ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... ... November 25, 2015 , ... Castlewood ... people struggling with eating disorders as a result of the $20,000 raised at ... held at Fox Run Golf Club in Eureka, will help individuals who otherwise ...
Breaking Medicine News(10 mins):